The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial
Open accessAbstract
Summary Background Afamitresgene autoleucel (afami-cel) showed acceptable safety and promising efficacy in a phase 1 trial (NCT03132922). This study evaluated afami-cel’s efficacy in human leukocyte antigen (HLA)-A*02–positive patients with melanoma-associated antigen A4 (MAGE-A4)-expressing advanced synovial sarcoma or myxoid/round cell liposarcomas (MRCLS). Methods Cohort 1 of this ongoing, single-arm, open-label, phase 2 trial evaluated a single intravenous afami-cel dose after lymphodepletion in HLA-A*02–positive adult patients with metastatic/unresectable synovial sarcoma or MRCLS expressing MAGE-A4 who had received ≥1 prior line of anthracycline and/or ifosfamide-containing chemotherapy. Primary endpoint was overall response rate in cohort 1, determined by a blinded committee using Response Evaluation Criteria in Solid Tumours version 1·1 in the modified intent-to-treat population. Adverse events (AEs), including those of special interest (cytokine release syndrome, prolonged/pan-cytopenia, neurotoxicity) were monitored. Trial is registered at ClinicalTrials.gov, number NCT04044768. Findings Between 17 December 2019 and 27 July 2021, 52 patients with cytogenetically confirmed synovial sarcoma (n=44) and MRCLS (n=8) were enrolled and received afami-cel in cohort 1. Baseline median MAGE-A4 expression P-score was 83·5 (IQR 62–99) overall and 89·5 in patients with synovial sarcoma; H-score was 231·5 (IQR 174–294) overall and 256·5 in patients with synovial sarcoma. Patients were heavily pre-treated (median 3 [IQR 2–4] prior lines of systemic therapy). Overall response rate was 37% (19 of 52; 95% CI 23·62–51·04) overall, 39% (17 of 44) in synovial sarcoma, and 25% (2 of 8) in MRCLS; median follow-up time, 32·6 months (IQR 29–36). Cytokine release syndrome occurred in 71% (37 of 52) of patients (one grade 3 event). Cytopenias were the most common grade ≥3 AEs (lymphopenia in 50 [96%], neutropenia 44 [85%], leukopenia 42 [81%] of 52). Interpretation Afami-cel treatment resulted in durable responses in heavily pre-treated HLA-A*02–positive patients with MAGE-A4–expressing synovial sarcoma. Grade 1/2 cytokine release syndrome and grade 3/4 haematologic toxicities were common. Funding Adaptimmune.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452
Self-citationFusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma
Crozat, A., Åman, P., Mandahl, N., & Ron, D. (1993) · Nature · doi:10.1038/363640a0 · Cited by 894
Sleijfer, S., Ray-Coquard, I., Papai, Z., Le Cesne, A., Scurr, M., Schöffski, P., Collin, F., Pandite, L., Marreaud, S., De Brauwer, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3223 · Cited by 679
Self-citationRejeski, K., Perez, A., Sesques, P., Hoster, E., Berger, C., Jentzsch, L., Mougiakakos, D., Frölich, L., Ackermann, J., Bücklein, V., et al. (2021) · Blood · doi:10.1182/blood.2020010543 · Cited by 475
D'Angelo, S. P., Melchiori, L., Merchant, M. S., Bernstein, D., Glod, J., Kaplan, R., Grupp, S., Tap, W. D., Chagin, K., Binder, G. K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1417 · Cited by 435
Self-citationRearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11)
Åman, P., Ron, D., Mandahl, N., Fioretos, T., Heim, S., Arheden, K., Willén, H., Rydholm, A., & Mitelman, F. (1992) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870050403 · Cited by 298
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
Malekzadeh, P., Pasetto, A., Robbins, P. F., Parkhurst, M. R., Paria, B. C., Jia, L., Gartner, J. J., Hill, V., Yu, Z., Restifo, N. P., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123791 · Cited by 275
Pollack, S. M., He, Q., Yearley, J. H., Emerson, R., Vignali, M., Zhang, Y., Redman, M. W., Baker, K. K., Cooper, S., Donahue, B., et al. (2017) · Cancer · doi:10.1002/cncr.30726 · Cited by 274
Self-citationde Pinieux, G., Karanian, M., Le Loarer, F., Le Guellec, S., Chabaud, S., Terrier, P., Bouvier, C., Batistella, M., Neuville, A., Robin, Y.-M., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0246958 · Cited by 269
Self-citation
Cited by
CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review
Brudno, J. N., Maus, M. V., & Hinrichs, C. S. (2024) · JAMA · doi:10.1001/jama.2024.19462 · Cited by 359
CAR-T cell therapy for cancer: current challenges and future directions
Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens-Arias, V., Diaz-Beya, M., Juan, M., Urbano-Ispizua, Á., Esteve, J., Velasco-Hernandez, T., & Menéndez, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 281
Metadata
- Authors
- D'Angelo, S. P., Araujo, D. M., Abdul Razak, A. R., Agulnik, M., Attia, S., Blay, J.-Y., Carrasco Garcia, I., Charlson, J. A., Choy, E., Demetri, G. D., Druta, M., Forcade, E., Ganjoo, K. N., Glod, J., Keedy, V. L., Le Cesne, A., Liebner, D. A., Moreno, V., Pollack, S. M., Schuetze, S. M., Schwartz, G. K., Strauss, S. J., Tap, W. D., Thistlethwaite, F., Valverde Morales, C. M., Wagner, M. J., Wilky, B. A., McAlpine, C., Hudson, L., Navenot, J.-M., Wang, T., Bai, J., Rafail, S., Wang, R., Sun, A., Fernandes, L., Van Winkle, E., Elefant, E., Lunt, C., Norry, E., Williams, D., Biswas, S., & Van Tine, B. A.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2024-04
- Volume
- 403
- Issue
- 10435
- Pages
- 1460-1471
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4393238683
- Cited by
- 297
- References
- 20
- FWCI
- 45.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(24)00319-2
- The paper
- D'Angelo, S. P., Araujo, D. M., Abdul Razak, A. R., Agulnik, M., Attia, S., Blay, J.-Y., Carrasco Garcia, I., Charlson, J. A., Choy, E., Demetri, G. D., Druta, M., Forcade, E., Ganjoo, K. N., Glod, J., Keedy, V. L., Le Cesne, A., Liebner, D. A., Moreno, V., Pollack, S. M., . . . Van Tine, B. A. (2024). Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. The Lancet. https://doi.org/10.1016/s0140-6736(24)00319-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.